Vascular anomalies (VA) are developmental anomalies of veins, arteries, lymphatics or capillaries thought to be caused by mutations in genes that drive angiogenesis. Treatments targeting these genes are limited. We review the literature for conventional medications and products from traditional medicine cultures that have been found to have antiangiogenic activity. Fewer than 50 drugs with credible human activity in VA were identified and include β blockers, monoclonal antibodies, microtubule inhibitors, multi-kinase inhibitors, PIK3CA- and RAS-MAPK pathway inhibitors, and thalidomides. Other drug categories of potential interest are ACE-inhibitors, antifungals, antimalarials, MMP9-inhibitors, and over-the-counter compounds used in Eastern traditional medicine. Low toxicity for some offers the possibility of combined use with known effective agents. In addition to already familiar drugs, others with antiangiogenic capabilities already in use in children or adults may deserve further attention for repurposing for VA.

血管异常(VA) 是静脉、动脉、淋巴管或毛细血管的发育异常，被认为是由驱动血管生成的基因突变引起的。针对这些基因的治疗是有限的。我们回顾了已发现具有抗血管生成活性的传统药物和传统医学文化产品的文献。已鉴定出不到 50 种在 VA 中具有可信人体活性的药物，包括 β 受体阻滞剂、单克隆抗体、微管抑制剂、多激酶抑制剂、 PIK3CA和RAS-MAPK通路抑制剂以及沙利度胺。其他可能感兴趣的药物类别包括 ACE 抑制剂、抗真菌药、抗疟药、MMP9抑制剂以及东方传统医学中使用的非处方化合物。对某些人来说低毒性提供了与已知有效药物联合使用的可能性。除了已经熟悉的药物外，其他已在儿童或成人中使用的具有抗血管生成能力的药物可能值得进一步关注，以重新用于 VA。